The purpose of this study was to clarify the significance of recipient gender status on lung transplant outcomes in a large single-institution experience spanning three decades, we analyzed data from all lung transplants performed in our institution since 1986. Kaplan-Meier curves and Cox proportional hazard models were used to evaluate the effect of recipient characteristics on survival and BOS score ≥1-free survival. 
| INTRODUCTION
Understanding factors associated with reduced long-term survival after lung transplants is important for predicting, and potentially improving, outcomes. Currently, the average unadjusted 5-year survival rate remains low: 56%. 1 Several factors have been implicated in reduced long-term survival, such as primary graft dysfunction (PGD), certain primary diagnoses, older recipient age, frailty, donor-recipient human leukocyte antigen (HLA) mismatches, elevated body mass index (BMI), and single-lung transplants. [1] [2] [3] [4] [5] The biologic and psychosocial differences between the genders can also uniquely affect outcomes post-transplant.
Several studies have demonstrated improved survival rates for female (as compared to male) recipients. Roberts and colleagues showed a 5-year survival of 65% for female recipients, as compared to 40% for male recipients. 6 In a single-center cohort analysis, Demir and colleagues observed a similar difference between female and male recipients. 7 In contrast, in their review of a large International Society for Heart and Lung Transplantation (ISHLT) registry of 18 702 patients, mostly in the pre-LAS era, Gries and colleagues found no overall gender differences in survival. 8 Some have advocated that a donor-recipient gender mismatch is more important than the recipient gender alone.
Demir and colleagues showed that poor survival was associated with a female-to-male mismatch (ie, a female donor and a male recipient). 7 Likewise, in a multivariate analysis of the ISHLT registry, Sato and colleagues showed that a female-to-male mismatch was associated with a strong negative effect on long-term survival. 9 One reason might be that female donor organs, on average, have a lower functional mass than male donor organs. Thus, for improving outcomes and preventing PGD, appropriate donor-recipient size matching might be more relevant than donor-recipient gender matching per se. 10, 11 The initiation of the lung allocation score (LAS) in the United
States-by the United Network for Organ Sharing through the Organ Procurement and Transplantation Network-has changed the dynamics of the field, giving priority to higher-risk transplant candidates.
Since the beginning of the LAS era, a disproportionate number of lung recipients have been male. 1 Thus, the effect of male gender might be amplified by other characteristics that make recipients higher-risk, per the LAS. Moreover, female recipients might have protective mechanisms against long-term graft dysfunction. In this study, we analyzed the differences in characteristics and outcomes, particularly long-term survival post-transplant, between male and female recipients in the LAS era.
| MATERIALS AND METHODS

| Study design
For our retrospective analysis, we used the Transplant Information
Services database at the University of Minnesota, which includes prospectively collected information on all lung transplants at our institution from January 1986 through January 2016. For our study period, we intentionally spanned both the pre-LAS era (January 1986 through 
| Outcomes
Certain outcomes-such as the bronchiolitis obliterans score (BOS), peak PGD score, re-exploration for bleeding post-transplant, number of ventilator days post-transplant, and intensive care unit (ICU) length of stay (LOS)-were available only in the LAS era. For all recipients in the LAS era, an observer blinded to gender calculated the PGD scores (at time 0 and at 24, 48, and 72 hours), in accordance with the suggested ISHLT definition (PGD 3=PaO 2 :FiO 2 <200). 3 The primary outcome was overall survival; the secondary outcomes included development of bronchiolitis obliterans, peak PGD score in the first 72 hours, number of ventilator days post-transplant, ICU LOS, and hospital LOS.
| Statistical analysis
We tabulated overall descriptive statistics, by LAS era and by recipient gender. For continuous variables, we calculated the mean and standard deviation; for categorical variables, the frequency and percentage. Over a period of 10 years post-transplant, we analyzed overall survival, comparing male and female recipients. We summarized unadjusted differences in survival with a hazard ratio (HR), a 95%
confidence interval, and a P value, using a Cox proportional hazards model with only a single term for gender. 
| RESULTS
| Patient characteristics
Of the 876 lung transplants we analyzed, 501 were in the pre-LAS era;
375, in the LAS era.
In the pre-LAS era, 55.6% of the recipients were female. Of the 501 recipients in this era, 62.7% of the females and 57.2% of the males underwent single-lung transplants; 16.1% of the females and 20.7% of the males were at least 60 years old at the time of their transplant ( had a BMI<20. There were 81 short stature women (<162 cm) (~45% of LAS era women) compared to four short stature men (~2% of LAS era men). We saw no qualitative differences in patient characteristics between short females and normal-height females.
Only 14.5% of the females, as compared to 19.9% of the males, had an LAS≥50. Similar percentages received a lung from a smoker:
32.4% of the females and 31.6% of the males. Ischemic times were slightly shorter for the females (mean, 292 minutes) than for the males (mean, 314 minutes). But we observed no significant gender differences related to socioeconomic status, although males were more likely to pursue graduate-level education than females and were less likely to have been on disability at the time of the transplant ( Table 2) . Values presented as N or n (%), except superscript 'a'=mean (standard deviation).
(-) indicates excluded entries due to excessive missing values (>50%); alpha 1 =alpha 1 -antitrypsin deficiency; BMI, body mass index; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; isch, ischemic; LAS, lung allocation score; PA BP, pulmonary artery blood pressure; Recip, recipient; tx, transplant.
| Unadjusted survival
Overall, for both eras, the 5-and 10-year survival rates were similar by gender: 59% and 33% for females, as compared to 56% and 33% for males ( Figure 1 ). In the pre-LAS era, the 1-and 5-year survival rates were nearly identical by gender: 77% and 52%, as compared to 77%
and 54% for males ( Figure 2 ).
But in the LAS era, the 1-and 5-year survival rates diverged:
90% and 71% for females, as compared to 86% and 58% for males (P=.011) (Figure 3 ). And donor-recipient gender mismatches widened the gap in the 5-year survival rates even further: 61% for maleto-male matches and 43% for female-to-male mismatches (P=.02) (Figure 4 ).
In the LAS era, 11.2% of the females, as compared to 17.9% of the males, underwent re-exploration for bleeding post-transplant ( 
| Adjusted survival
Among the 876 recipients in our entire cohort (covering both eras), only two risk factors were independently associated with lower However, the HR for 5-year survival in female recipients varied from 1.04 (P=.75) in the pre-LAS era to 0.56 (P=.03) in the LAS era.
In the LAS era, male recipient gender was the only independent predictor of lower 5-year survival rates. In our analysis of the LAS era, we also adjusted for LAS score, peak PGD score in the first 72 hours of 3, BMI, and eGFR≥60 at the time of the transplant. In our analysis adjusting for female-to-male mismatches, the HR was 1.88 for femaleto-male (vs. male-to-male) mismatches (P=.06). Recipient female gender remained the only independent predictor of improved long-term survival (Table 5 ). Short stature females (<162 cm) had worse survival than normal-size females after transplant in our adjusted analysis but both survived longer than males.
In the LAS era, the adjusted odds ratio for re-exploration for bleeding 
| Gender effects on bronchiolitis obliteransfree survival
In the LAS era, the 1-and 5-year rates of bronchiolitis obliterans-free survival were 75% and 35% for female recipients, as compared to 65% and 25% for male recipients (P=.02) ( Figure 5 ). In our unadjusted analysis, the HR was 1.4 for male (vs. female) recipients (P=.013) and
for single-lung (vs. bilateral) transplants (P=.039). In our adjusted
analysis, the only two factors associated with improved bronchiolitis obliterans-free survival that neared statistical significance were female gender and higher LAS. The HR for male (vs. female) recipients was 1.43 (P=.07) and for an LAS increase ≥10 was 1.08 (P=.074). a lower (by 75%) incidence of severe graft rejection, as compared to male recipients. 13 In female recipients of a heart transplant or a lung transplant, a survival advantage over male recipients has been noted (although that advantage is largely accounted for by the negative influence of female-to-male mismatches). 14, 15 In the field of lung transplantation, several, but not all, authors have observed a survival advantage for female recipients. 6, 7, 16 As noted above, Gries and colleagues-in their review of a large ISHLT registry of 18 072 patients, mostly in the pre-LAS era-found no overall gender differences in survival. 8 Their finding is consistent with ours: We observed a similar survival rate between male and female recipients in the pre-LAS era and in both eras combined. Our study adds to the growing body of evidence showing improved outcomes in female lung transplant recipients, but highlights an important transition that occurred in the LAS era.
Since the beginning of the LAS era, national waitlist deaths have decreased from 500 per year to 300 per year, and the number of lung transplants performed annually has doubled. 17 Those improvements have come with the change in the makeup of lung transplant recipients: They are now more likely to be male, to be more seriously ill, and CF, cystic fibrosis; CI, confidence interval; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio; IPF, idiopathic pulmonary fibrosis; LAS, lung allocation score; PGD, primary graft dysfunction; recip, recipient; tx, transplant. to be older than they were in the pre-LAS era. 1, 18 In the LAS era, the national 1-year survival rate has seen a small but statistically significant increase; however, the 5-year survival rate continues to be low, with an unadjusted average of 56%. 1 Our institution's data parallel those findings: We, too, noted an increased proportion of sicker and older male recipients in the LAS era, as compared to the pre-LAS era.
T A B L E 3 Patient outcomes
Thus, although we adjusted for that demographic change, our findings might simply reflect a higher proportion of sicker and older male recipients in our cohort in the LAS era.
Several theoretical reasons could help explain why female recipients might have better long-term outcomes. One reason has to do with donor-recipient gender mismatches. As noted above, Demir and colleagues showed that poor survival was associated with a female-to-male mismatch. 7 A similar negative impact of female-tomale mismatches has also been shown in liver and heart transplant recipients. 14, 15 In our study, we also saw a negative impact on survival associated with female-to-male mismatches. Female donors tend to be smaller in size than male donors; this size discrepancy can contribute to PGD. 10, 11, 19 In our study, female recipients had a higher rate of bronchiolitis obliterans-free survival than male recipients. That alone could certainly explain their overall survival benefit. During pregnancy, females demonstrate tolerance for alloantigens. The underlying mechanism is unclear, but it may contribute to improved tolerance after solid organ transplants. Elevated estrogen levels might be protective against longterm rejection. In experimental studies, rats treated with high-dose estradiol were resistant to chronic rejection after orthotopic kidney transplants. 21 Interestingly, we saw a greater rate of re-exploration for bleeding post-transplant in male recipients than in female recipients. We did not record data on the indications for re-exploration, but in general, the vast majority is due to hemothorax and wound revisions. In cardiac F I G U R E 5 Bronchiolitis obliterans-free patient survival, LAS era. yr, years post-transplant surgery patients, re-exploration for bleeding has been shown to be a significant factor in reducing long-term survival. 22 Thus, after lung transplants, it may be especially important in male recipients to be meticulous about hemostasis.
Despite improved long-term outcomes in female lung transplant recipients, several authors have documented an increased incidence of PGD and worse long-term quality of life. Diamond and colleagues noted a trend toward an increased incidence of PGD in female lung transplant recipients with more than two pregnancies. 23 A metaanalysis by Lanuza and colleagues found an odds ratio of 1.38 (P=.008)
for PGD in female lung transplant recipients, who accounted for the majority (55%) of PGD events. In our study, female recipients (despite their lower mean number of ventilator days post-transplant) also had a higher incidence of a peak PGD score of 3 in the first 72 hours, as compared to male recipients. Conceivably, hormonal differences account for the differences in PGD, while other factors such as size and reoperations accounted for the differences in ventilator days.
Moreover, quality of life studies of lung transplant recipients suggests that males have lower stress levels post-transplant and decreased mood disturbances than females. 24 Rodriguez and colleagues reported worse health-related quality of life gains in females than in males, but better long-term spirometry results in females than in males. 25 In our study, we attempted to explore socioeconomic factors that might be different between the genders at baseline in the LAS era, but found no differences.
| Study limitations
Our study is subject to the biases and confounding factors inherent in a retrospective cohort design. Nonetheless, those limitations are counterbalanced by our single-institution analysis, with consistent perioperative practices around surgical technique, post-operative care, and immunosuppression.
Like most lung transplant programs, we did refine our protocols over time, but they have stayed very consistent in the LAS era. We did not collect blood transfusion records in this study. It is conceivable that our male lung transplant recipients (given their higher reexploration rate) received more blood products, which could account for differences in long-term survival. Also, controlling for the LAS score causes a dilemma. On the one hand, it provides a helpful and simple description of the degree of illness prior to transplant. There were greater comorbidities in the male cohort in the LAS era and no other factor could describe this difference better than the LAS. On the other hand, adjusting for LAS also counts certain variables such as age and diagnosis twice which could unfairly penalize the male cohort.
Without adjusting for LAS, the hazard ratio becomes even greater for the males in the latter era.
| CONCLUSION
In our large single-institution study spanning three decades, male recipient gender was significantly associated with decreased long-term survival and increased bronchiolitis obliterans-free survival after lung transplants. Those findings were most evident in the LAS era. The negative effect of male recipient gender might have been exacerbated by increased comorbidity in the LAS era and/or by the positive (but not clearly understood) effect of female recipient gender. The commendably high long-term survival for female lung transplant recipients at 5 years merits additional investigation. A prospective analysis of biologic and immunologic characteristics of male and female lung transplant recipients is warranted. Furthermore, considerable attention to pre-transplant optimization and selection of male lung transplant recipients, as well as to operative hemostasis, could improve their long-term outcomes.
